Despite a recent rough trot, you'll be amazed to know what $5,000 of Polynovo shares bought 5 years ago is worth now

How much would an investor have pocketed if they bought Polynovo shares 5 years ago.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The company’s share price has been hammered over the year, but is still up over the long run 
  • An initial investment of $5,000 would have reaped over $22,000 
  • The ASX 200 has generated a yearly average return of 4.97% over five years compared to 34.52% for Polynovo 

Despite recently falling on hard times, the Polynovo Ltd (ASX: PNV) share price has been a star performer over the long term.

Arguably, investing your money in businesses that are either new to the market or emerging can reap some serious rewards. Of course, there is an inherent risk, particularly given that the medical device company was outside the S&P/ASX 200 Index (ASX: XJO).

Below, we calculate how much you would have made if you'd bought $5,000 worth of Polynovo shares five years ago.

Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

How much would your initial investment be worth now?

If you'd invested $5,000 into Polynovo shares in 2017, you would have picked them up for approximately 23.5 cents apiece. This equates to about 21,276 shares without topping up along the way during the retracement periods.

Fast-forward to today, Polynovo shares closed at $1.035 on Friday. This means those 21,276 shares would be worth a staggering $22,020.66.

When looking at percentage terms, this implies a gain of 340% or an average yearly return of 34.52%.

In comparison, investing the same amount in an ASX 200 index-tracking fund would have given back 26.33% over 5 years. This equates to an average of 4.97% per year.

If you are wondering about Polynovo dividends, the company has chosen not to pay a percentage of its profits to date. Instead, it has decided to expand its geographical spread and increase brand investment to drive consumer demand.

Polynovo share price snapshot

Over the past 12 months, the Polynovo share price has travelled 66% lower and is down 31% year to date.

The company's shares hit a 52-week low of 83.5 cents in March before moving in a sideways channel of late.

Polynovo presides a market capitalisation of roughly $686.5 million and has more than 661.68 million shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »

Health professional looking at a laptop.
Earnings Results

Cogstate posts record FY26 earnings, boosts dividend

Cogstate delivers record FY26 earnings growth and increases its dividend as it invests in AI-driven expansion.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

CSL earnings: FY26 sees reset and path to future growth

The biotech giant has released its eagerly anticipated results this morning.

Read more »

A man looking at his laptop and thinking.
Earnings Results

Cochlear posts FY26 profit at top end of guidance with new product momentum

Management is guiding to a profit rebound in FY 2027.

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Mesoblast shares are up sharply. Is this biotech still undervalued?

Mesoblast faces big risks, but brokers see substantial upside if successful.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »